STOCK TITAN

PHAXIAM THERAPEUTICS S A - PHXM STOCK NEWS

Welcome to our dedicated page for PHAXIAM THERAPEUTICS S A news (Ticker: PHXM), a resource for investors and traders seeking the latest updates and insights on PHAXIAM THERAPEUTICS S A stock.

PHAXIAM Therapeutics S.A. (PHXM) is a pioneering biopharmaceutical company specializing in the development of innovative therapies to address unmet medical needs, particularly in the fields of oncology and orphan diseases. Founded in 2004, the company leverages its proprietary technology to encapsulate therapeutic molecules into red blood cells, offering a novel approach to drug delivery. This encapsulation technology provides several advantages over traditional free-form compounds, including reduced potential for allergic reactions and prolonged drug efficacy within the body. By utilizing this cutting-edge methodology, PHAXIAM aims to transform the treatment landscape for patients with severe and life-threatening conditions.

The company's flagship product, designed to combat cancer by 'starving' tumors, has successfully completed Phase III clinical development. This therapeutic innovation is particularly targeted at patients with relapsed and refractory acute lymphoblastic leukemia, a critical area of unmet need in oncology. PHAXIAM's focus on orphan diseases further underscores its commitment to addressing rare conditions that often lack effective treatment options.

PHAXIAM operates a state-of-the-art production facility in Lyon, France, which holds 'pharmaceutical establishment' status. This facility not only supports the company’s manufacturing needs but also ensures compliance with stringent regulatory standards, enabling scalability for broader distribution. The company has also established strategic distribution partnerships with Orphan Europe-Recordati in Europe and Teva in Israel, facilitating access to its therapies across key markets.

Operating within the highly specialized biopharmaceutical sector, PHAXIAM is positioned at the intersection of innovation and patient-centric care. The company's focus on encapsulation technology differentiates it within the competitive landscape, offering a unique value proposition that addresses both efficacy and safety concerns. By targeting niche markets such as oncology and orphan diseases, PHAXIAM minimizes direct competition while addressing high-impact medical challenges.

PHAXIAM Therapeutics S.A. exemplifies the convergence of cutting-edge science, robust manufacturing capabilities, and strategic partnerships. Its commitment to leveraging innovative technologies to address critical medical needs positions it as a significant player in the biopharmaceutical industry.

Rhea-AI Summary
PHXM releases monthly information on total voting rights and share capital, showing stability in figures for February 2024. The company is listed on Euronext Paris and Nasdaq Global Select Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.4%
Tags
none
-
Rhea-AI Summary
PHAXIAM Therapeutics plans to voluntarily delist its American Depositary Shares from The Nasdaq Capital Market, focusing on Euronext Paris as its primary trading market. The delisting aims to reduce cash utilization and redirect resources towards key development milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.33%
Tags
none
-
Rhea-AI Summary
Pharnext, a biopharmaceutical company listed on Euronext Paris and Nasdaq, recently released a press release regarding the declaration of voting rights for the company's shares. The company's total shares and voting rights as of December 31, 2023, and January 31, 2024, were disclosed in accordance with the general regulation of French Autorité des Marchés Financiers. The press release provides the ISIN code and symbols for the company's shares on both Euronext and Nasdaq, along with the company's website. The release also explains the calculation of gross voting rights and net voting rights, including the treatment of shares with and without voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
Rhea-AI Summary
PHAXIAM Therapeutics announces a cash position of €10.5 million as of December 31, 2023, enabling the company to fund its programs and expected operating expenses until July 2024. The company also plans to refinance in the first half of 2024. Additionally, the financial calendar for 2024 includes updates on business and key financial data for each quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pharnext (PHXM) Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - December 31, 2023. Pharnext, listed on Euronext Paris and Nasdaq Global Select Market, released monthly information related to the total number of voting rights and shares composing the share capital. The total of shares composing the share capital, total of brut and net voting rights, and the dates are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary
Monthly information related to total number of voting rights and shares composing the share capital for Phaxiam (PHXM) on Euronext Paris and Nasdaq Global Select Market. As of November 30, 2023, the total number of shares composing the share capital was 6,075,105 with 6,225,121 brut (1) voting rights and 6,225,872 net (2) voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
Rhea-AI Summary
PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) provides a business and financial update for the third quarter of 2023, highlighting clinical development progress, financial figures, and upcoming milestones. The company aims to become a global phage therapy leader in high-value indications and has made significant advancements in its clinical and regulatory strategy, real-life activity data, and proprietary platform efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pharnext (PHXM) reports changes in voting rights, with a significant increase in the number of shares composing the share capital and voting rights in May and June 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.01%
Tags
none
-
Rhea-AI Summary
PHAXIAM Therapeutics receives approval for phase 1 study design in endocarditis infections caused by S. aureus
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
Rhea-AI Summary
PHAXIAM Therapeutics receives coverage initiation from TP ICAP Midcap with a 'Buy' recommendation and a valuation of €8.5 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.31%
Tags
none

FAQ

What is the market cap of PHAXIAM THERAPEUTICS S A (PHXM)?

The market cap of PHAXIAM THERAPEUTICS S A (PHXM) is approximately 19.9M.

What does PHAXIAM Therapeutics S.A. specialize in?

PHAXIAM Therapeutics specializes in developing innovative therapies for oncology and orphan diseases using its proprietary encapsulation technology.

How does PHAXIAM's encapsulation technology work?

The technology encapsulates therapeutic molecules into red blood cells, reducing allergic reactions and prolonging drug efficacy within the body.

What markets does PHAXIAM target?

PHAXIAM targets oncology and orphan diseases, focusing on areas with significant unmet medical needs.

Who are PHAXIAM's distribution partners?

PHAXIAM has partnered with Orphan Europe-Recordati for European distribution and Teva for distribution in Israel.

Where is PHAXIAM's production facility located?

PHAXIAM operates a pharmaceutical establishment-certified production facility in Lyon, France.

What differentiates PHAXIAM from its competitors?

PHAXIAM's proprietary encapsulation technology offers unique advantages, such as reduced allergic reactions and prolonged drug efficacy, setting it apart in the biopharma industry.

What is PHAXIAM's flagship product?

PHAXIAM's flagship product is a therapy designed to 'starve' tumors, targeting patients with relapsed and refractory acute lymphoblastic leukemia.

What challenges does PHAXIAM face in its market?

PHAXIAM faces challenges like dependency on clinical trial outcomes, regulatory approvals, and competition within the specialized biopharma sector.

What is the significance of PHAXIAM's production facility?

The Lyon-based facility ensures compliance with regulatory standards and supports scalable manufacturing for broader distribution.

What is PHAXIAM’s competitive advantage?

PHAXIAM’s competitive advantage lies in its encapsulation technology, which enhances drug safety and efficacy while addressing critical unmet medical needs.
PHAXIAM THERAPEUTICS S A

Nasdaq:PHXM

PHXM Rankings

PHXM Stock Data

19.86M
6.07M
2.69%
0.02%
Biotechnology
Healthcare
Link
France
Lyon